Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.
Department of Rheumatology, CHU d'Amiens, University of Picardie Jules Verne, 80054 Amiens, France; Department of Rheumatology, CHU de Rouen, University of Rouen, 76031 Rouen, France. Electronic address: totobanse@orange.fr.
Christopher
C
Banse
Department of Rheumatology, CHU d'Amiens, University of Picardie Jules Verne, 80054 Amiens, France; Unité Inserm U1088, Université de Picardie-Jules-Verne, 80054 Amiens, France.
Patrice
P
Fardellone
Department of Rheumatology, CHU d'Amiens, University of Picardie Jules Verne, 80054 Amiens, France; Unité Inserm U1088, Université de Picardie-Jules-Verne, 80054 Amiens, France.
Julien
J
Paccou
D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D000069465:Febuxostat; D005260:Female; D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006074:Gout Suppressants / Q000627:therapeutic use*; D019983:Guideline Adherence; D006760:Hospitalization; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy*; D008297:Male; D015995:Prevalence; D013844:Thiazoles / Q000627:therapeutic use; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
D006074:Gout Suppressants; D013844:Thiazoles; D000069465:Febuxostat; D000493:Allopurinol; D014969:Xanthine Oxidase
Allopurinol; Asymptomatic hyperuricaemia; Comorbidities; Febuxostat; Gout; Urate-lowering therapy